- Oral presentation
- Open Access
0312. Host genetics of HCV disease — IL28B
- J Fellay1
© Fellay; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Co-infections with HCV and HIV are common, because both viruses share routes of transmission and establish chronic infections. The standard treatment for chronic hepatitis C, a combination of peginterferon-α and ribavirin, is poorly tolerated and only successful in about half of the treated patients. Thus, identification of accurate predictors of treatment response is highly desirable.
Several independent genome-wide association studies have recently identified human genetic variants around the IL28B gene (coding for IFN-λ3) that strongly associate with spontaneous clearance of HCV and with treatment success, both in HCV mono-infected and in co-infected patients. I will put these findings in perspective and discuss their practical and theoretical implications with regard to drug development, clinical trial design and clinical management of chronic HCV infection. Results of detailed genetic and functional analyses of the IL28B gene region will also be presented.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.